India, Feb. 6 -- While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, adjusted earnings and revenue guidance for the full-year 2025, in line with analysts' estimates.
For fiscal 2025, Eli Lilly now projects earnings in a range of $22.05 to $23.55 per share and adjusted earnings in a range of $22.50 to $24.00 per share on revenues between $58.0 billion and $61.0 billion.
On average, analysts polled expect the company to report earnings of $22.69 per share on revenues of $58.91 billion for the year. Analysts' estimates typically exclude special items.
The company said the growth in revenue compared to 2024 is expected to be largely driven by new Lilly medicines such...